In Lilly Bio-Medicines, our vision is that by 2020, we will change patient expectations in some of the world’s most debilitating disease areas. We’re not defined by one therapeutic area, but by diseases that have significant unmet needs. And we’re working to deliver new therapies that we believe will shift the frontiers of medicine and what’s possible for patients – specifically in the areas of Alzheimer’s disease, immunology and pain.
Unlike Lilly’s other business units, which focus in a specific disease area, Bio-Medicines is unique and diversified. We have medicines on the market in the areas of psoriasis, neuroscience, osteoporosis, cardiovascular, and men’s health, and we’re responsible for about 40 percent of Lilly’s worldwide revenue. We’re also home to half of Lilly’s late-stage development pipeline, with medicines in late-stage clinical studies or under regulatory review for rheumatoid arthritis, Alzheimer’s disease, psoriatic arthritis, axial spondyloarthritis, migraine, cluster headache and chronic pain.
Bio-Medicines also house the leadership and operational structure for Lilly affiliates in the world’s largest pharmaceutical markets: the United States, Europe and Japan.